Status:
UNKNOWN
Assessment of the Link Between Monomeric Functional Form Plasma Level of Vasostatin-1 and Occurrence of New Onset Atrial Fibrillation in Severe Intensive Care Patients
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Atrial Fibrillation
Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Atrial fibrillation (AF) is a cardiac rhythm disorder particularly common in intensive care patients. Some meta-analyzes report a prevalence of new onset AF ranging from 4.5% to 29.5% in polyvalent in...
Eligibility Criteria
Inclusion
- Major patients (no upper age limit), male or female.
- Consenting to participate in the study (consent sought from the person of trust in case of inability to consent). Informed consent was given in writing.
- Subject affiliated to a social health insurance regiment
- Presenting a state of shock characterized by a SAP \<90mmHg or MAP \<65mmHg despite 1000ml of fluid resuscitation and requiring the use of norepinephrine to obtain a SAP \>90mmHg or MAP \>65mmHg.
- arterial lactatemia is greater than 2mmol / L at baseline
- equipped with radial or femoral arterial catheter (set up as part of the usual care)
Exclusion
- Refusal to participate in the study
- Patient subject to legal protection (guardianship, curatorship or legal safeguards)
- Pregnant patient
- History of paroxysmal or permanent FA
- Recent history of cardiac surgery (\<15 days)
Key Trial Info
Start Date :
June 18 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03457155
Start Date
June 18 2018
End Date
July 1 2023
Last Update
August 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpitaux Universitaires de Strasbourg
Strasbourg, France